- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04591613
Late Clinical Events Associated With COVID-19 Infection (COCO-LATE)
Late Clinical Events Associated With COVID-19 Infection: Multicenter Cohort
Several publications document the occurrence of symptoms that persist or occur late.
The identification of the observed clinical manifestations and their clinical and paraclinical description are essential to better understand the natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible late manifestations, and to identify potential management options for patients.
Since this type of event is infrequent, a large-scale national multicenter cohort study focusing on symptomatic patients is needed.
연구 개요
상세 설명
Several publications document the occurrence of symptoms that persist or occur late, more than 3 weeks after the first clinical manifestations of an SARS-COV2 infection. These manifestations may be related to thromboembolic or inflammatory complications, superinfections, or other mechanisms not yet well understood, including potentially related to the persistence of SARS-COV2. The identification of the observed clinical manifestations and their clinical and paraclinical description are essential to better understand the natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible late manifestations, and to identify potential management options for patients.
Since this type of event is infrequent, a large-scale national multicenter cohort study focusing on symptomatic patients is needed. In parallel, the prevalence of the main symptoms observed more than 3 weeks after the onset of a COVID-19 will be estimated through partnerships with existing cohort studies in the general population or in the population followed for COVID-19, still symptomatic or not at 3 weeks of infection.
Longitudinal implementation of bio-libraries will allow this cohort to also constitute a bridge between clinicians and researchers.
연구 유형
등록 (예상)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Olivier ROBINEAU, MD PhD
- 전화번호: 0320694949
- 이메일: orobineau@ch-tourcoing.fr
연구 장소
-
-
-
Auxerre, 프랑스
- 모병
- Ch Auxerre
-
Caen, 프랑스
- 모병
- CHU caen
-
Lille, 프랑스
- 모병
- CHRU Lille
-
Melun, 프랑스
- 모병
- CH Melun Marc Jacquet
-
Nemours, 프랑스
- 모병
- CH Sud Seine et Marne
-
Paris, 프랑스
- 아직 모집하지 않음
- AP-HP Hôpital Hôtel-Dieu
-
Saint-Priest-en-Jarez, 프랑스
- 모병
- CHU DE SAINT-ETIENNE
-
Tourcoing, 프랑스
- 모병
- Ch Tourcoing
-
Tours, 프랑스
- 모병
- CHRU Tours
-
Vandœuvre-lès-Nancy, 프랑스
- 모병
- CHRU Nancy
-
Vannes, 프랑스
- 모병
- Centre Hospitalier Bretagne Atlantique
-
-
-
-
-
Cayenne, 프랑스령 기아나
- 모병
- CH André Rosemon de Cayenne
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
History of symptomatic CoV-2-SARS infection as defined by :
o Positive RT-PCR SARS-CoV-2 RT-PCR result OR positive SARS-CoV-2 serology
o Associated with at least one event : x Anosmia occurring after February 2020 x OR COVID 19 evocative scanner x OR ≥ 2 contemporary symptoms of the virological sample from: asthenia, cough, dyspnea, fever, myalgia, dysgeusia, diarrhea AND not present prior to diagnosis
- AND persistence of at least one symptom present in the first 3 weeks of a COVID-19, more than 8 weeks away from the first symptoms of COVID-19. OR late onset of at least one new symptom a minimum of 3 weeks and a maximum of 6 months after the first symptoms of a CoV-2 SARS infection.
- First symptoms less than 6 months old on the day of inclusion
- To benefit from a State Health Insurance or Medical Aid plan
- Have signed an informed consent for inclusion.
Exclusion Criteria:
- Minor patient
- Patient under protection of justice
Patient who required intensive care management :
- more than 5 days
- OR requiring orotracheal intubation
- OR having required high flow ventilation (optiflow)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
다른: Standardized clinical and paraclinical follow-up
Standardized clinical and paraclinical follow-up will be offered in one of the referring investigator centers. Patients will be able to benefit from additional biological samples. Questionnaires will be completed by the patient or with the help of clinical research staff in paper format. All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID. Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits. Total serum, plasma and naso-paaryngeal samples will be collected. |
Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
Total serum, plasma samples will be collected
All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Clinical description of asthenia
기간: At the end od the study, an average of 22 months
|
Describe the frequence of asthenia between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
Clinical description of dyspnea
기간: At the end od the study, an average of 22 months
|
Frequence of dyspnea between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
Clinical description of thoracic disorders
기간: At the end od the study, an average of 22 months
|
Frequence of thoracic disorders between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
Clinical description of neurological disorders
기간: At the end od the study, an average of 22 months
|
Frequence of neurological disorders between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
Clinical description of anosmia
기간: At the end od the study, an average of 22 months
|
Frequence of anosmia disorders between its onset and its disappearance.
Assessment at baseline, then 4, 6 and 12 months.
Assessment at baseline, then 4, 6 and 12 months.
|
At the end od the study, an average of 22 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Olivier ROBINEAU, MD PhD, Ch Tourcoing
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- RIPH_2020_09
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
코로나19에 대한 임상 시험
-
Texas Woman's UniversityNational Institutes of Health (NIH)아직 모집하지 않음COVID19 테스트
-
Cairo UniversityKasr El Aini Hospital알려지지 않은
-
Assistance Publique - Hôpitaux de Paris알려지지 않은
-
Brugmann University Hospital모병
-
Istituti Clinici Scientifici Maugeri SpAIstituto Auxologico Italiano; Azienda Ospedaliera Bolognini di Seriate Bergamo; Azienda Socio... 그리고 다른 협력자들완전한
-
Abderrahmane Mami HospitalDacima Consulting; Eshmoun Clinical Research Center빼는
-
Aarhus University HospitalUniversity of Aarhus; Pharma Nord완전한
Questionnaire에 대한 임상 시험
-
University Hospital, Toulouse모병
-
Cambridge University Hospitals NHS Foundation TrustUniversity of Cambridge알려지지 않은근골격계 질환 | 근골격계 부상
-
Assistance Publique - Hôpitaux de Paris완전한
-
Medical University of Lublin완전한
-
Ankara Yildirim Beyazıt University모병
-
Istanbul Kültür UniversityMarmara University; Istanbul University - Cerrahpasa (IUC)완전한